Homozygous Familial Hypercholesterolemia

This is a rare genetic condition where a person's body makes too much LDL cholesterol. LDL is a type of fat in the blood that can build up in the arteries, increasing the risk of heart attacks and strokes. It's inherited, meaning you get it from your parents. Treatment is important to manage the high cholesterol and protect your heart health.

Condition

What people with Homozygous Familial Hypercholesterolemia report

Every report comes from a Lived member, sent anonymously.

Have you tried Crestor (Rosuvastatin) for Homozygous Familial Hypercholesterolemia?

NameHow it went

About Homozygous Familial Hypercholesterolemia

What It Is

Homozygous familial hypercholesterolemia (HoFH) is a rare inherited condition in which the body cannot clear LDL cholesterol from the blood, so levels are extremely high from before birth. LDL (low-density lipoprotein) is the so-called bad cholesterol that builds up as plaque inside artery walls. Because the exposure starts so early and is so intense, people with HoFH can develop narrowed heart arteries and other cardiovascular disease in childhood, the teenage years or early adulthood, decades sooner than usual. HoFH is the severe, two-copy form of familial hypercholesterolemia (FH). The common form, heterozygous FH, involves one altered gene, affects roughly 1 in 200 to 250 people, and causes high cholesterol that is serious but far less extreme. HoFH is much rarer, with an estimated 30,000 people affected worldwide. Cholesterol can also collect in the skin and tendons as yellowish lumps called xanthomas, which are often the first visible sign in a child. Without early, intensive treatment, the condition often shortens life, but modern treatment is changing that outlook.

Causes & Risk Factors

HoFH is caused by genes, not by diet or lifestyle. It develops when a person inherits a disease-causing change in a cholesterol-clearing gene from both parents. Most often the change is in the LDLR gene, which carries instructions for the LDL receptor, the protein liver cells use to pull LDL out of the bloodstream. Less often the APOB, PCSK9 or LDLRAP1 gene is involved. With two altered copies, the liver removes little LDL, so it builds up in the blood and is deposited in artery walls, tendons and skin. How much receptor activity remains differs from person to person. People with almost no working receptors tend to have the highest cholesterol and respond least to standard cholesterol medicines. Usually both parents have heterozygous FH, often without knowing it. In the rare recessive form linked to LDLRAP1, the parents typically have normal cholesterol. Smoking, diabetes and excess weight do not cause HoFH, but they add to the strain on arteries that are already under heavy pressure.

How It's Diagnosed

HoFH is usually first suspected from a lipid panel, a blood test that measures LDL cholesterol in milligrams per deciliter (mg/dL). For most adults, an LDL below 100 mg/dL is considered healthy. Under current European Atherosclerosis Society guidance, an untreated LDL above about 400 mg/dL suggests HoFH and calls for further evaluation, and levels are sometimes much higher. Xanthomas before age 10, or cholesterol levels in both parents consistent with FH, strengthen the suspicion. Because levels vary, a reading below 400 does not on its own rule HoFH out. Genetic testing can confirm the diagnosis by finding disease-causing changes in both copies of an FH gene, and the result helps predict how well certain medicines will work. Clinicians also rule out rarer conditions that can look similar, such as sitosterolemia, a different inherited disorder that responds to diet and medication in its own way. Once HoFH is diagnosed, a heart evaluation looks for narrowed coronary arteries and disease of the aortic valve, the valve through which blood leaves the heart. This usually includes an echocardiogram (an ultrasound of the heart) and, where available, a low-dose computed tomography (CT) scan of the heart arteries. Testing parents, brothers and sisters and other relatives, called cascade screening, can find family members with FH who also need treatment.

Treatment Options

Treatment starts as soon as HoFH is diagnosed, including in young children, because the goal is to cut lifelong LDL exposure as much as possible. Guidance sets an LDL goal below 70 mg/dL for adults and below 115 mg/dL for children and teens without established heart disease. These goals are hard to reach, so almost everyone needs several treatments at once, managed by a specialist lipid center. The usual starting point is a high-dose statin plus ezetimibe, two cholesterol-lowering pills. A PCSK9 inhibitor such as evolocumab (Repatha), an injection given every few weeks, may be added. All three depend on the liver's remaining LDL receptors, so they help some people substantially and others very little. PCSK9 inhibitors lower LDL by about 30% on average, and most people still remain well above goal. Three other options work whether or not the receptors function. Evinacumab (Evkeeza) is an antibody given as an intravenous infusion once every 4 weeks. It lowered LDL by about half on top of other treatment in its main trial and is approved in the US from age 1. Lomitapide (Juxtapid) is a daily capsule that reduces the liver's production of the particles that become LDL; real-world use shows large but variable reductions. It requires a low-fat diet, very often causes digestive side effects, and can raise liver enzymes and liver fat, so regular liver blood tests are needed and it is available only through a restricted prescribing program. Lipoprotein apheresis uses a machine to filter LDL out of the blood and removes roughly half of it at each session. Sessions are time-consuming and usually repeat every one to two weeks, which is a real burden on school, work and family life, and cholesterol climbs back between treatments. Newer medicines can reduce how often it is needed. Beyond these, liver transplantation can normalize LDL but is reserved for rare severe cases, because surgery, rejection and lifelong immune-suppressing medicine carry serious risks. Gene-based treatments are being studied in clinical trials but are not established care.

What to Expect

HoFH is lifelong, and treatment is ongoing rather than a one-time fix. With current therapy, many people now live well into adulthood, and outlook depends heavily on how early treatment begins and how low LDL can be kept. Even so, heart disease can appear young: in a large international registry, the first major heart or blood vessel event occurred at a median age of 31. Regular follow-up includes blood tests to track LDL and medicine effects, and yearly echocardiograms of the heart and aorta. Narrowing of the aortic valve and the area just above it is common in HoFH and can keep progressing even when LDL is well controlled, so some people eventually need valve procedures or heart surgery at a specialist center. Treatment demands vary, from daily pills and monthly infusions to frequent apheresis, and quality of life is often affected by the time involved, worry about heart problems and the cost and availability of newer medicines. Family planning deserves early attention. Every child of a person with HoFH will inherit at least heterozygous FH, so testing a partner's cholesterol and genetic counseling are useful. For women with HoFH, pregnancy raises cardiovascular risk and can be life-threatening, LDL rises during pregnancy, and some HoFH medicines may harm a developing baby. Reliable contraception and planning with the specialist team before trying to conceive allow treatment, often including apheresis, to be adjusted safely.

When to Seek Help

Ask for a cholesterol test and specialist referral if a child or adult has very high LDL, yellowish lumps on the skin or tendons, or two parents with FH, and arrange testing for relatives once anyone in the family is diagnosed. People already being treated should see their care team if they are having trouble keeping up with treatment, have digestive side effects that make medicine hard to take, or are planning a pregnancy. Contact the care team promptly about chest discomfort with exercise, getting out of breath more easily than usual, or dizziness or fainting, especially during activity. These can be signs of narrowing heart arteries or a tightening aortic valve. Call 911 for chest pressure, squeezing or pain lasting more than a few minutes, or chest discomfort with shortness of breath, a cold sweat, nausea or pain spreading to the arm, back, neck or jaw. In HoFH, a heart attack can happen at a young age, so these symptoms need emergency care even in a teenager or young adult.

Questions to Ask Your Doctor

  1. 1.What is my current LDL level, what goal are we aiming for, and how close is my treatment getting me?
  2. 2.Does my genetic result suggest which medicines are likely to work well for me?
  3. 3.Would evinacumab, lomitapide or apheresis make sense for me, and how would each fit into my daily life?
  4. 4.How often should my heart arteries and aortic valve be checked, and what would change the plan?
  5. 5.Which of my relatives should be tested, and what should I know before planning a pregnancy?

Last reviewed • Oct 2026

Educational content, not medical advice.